This Morning's Technical Outlook on Medical Supplies Stocks -- TransEnterix, Akers Biosciences, Antares Pharma, and Microbot Medical
NEW YORK, Jan. 30, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on TRXC, AKER, ATRS, and MBOT which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 0.52%; the Dow Jones Industrial Average edged 0.67% lower; and the S&P 500 was down 0.67%. US markets made broad based losses with all sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Medical Instruments & Supplies stocks: TransEnterix Inc. (NYSE AMER: TRXC), Akers Biosciences Inc. (NASDAQ: AKER), Antares Pharma Inc. (NASDAQ: ATRS), and Microbot Medical Inc. (NASDAQ: MBOT). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
TransEnterix
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished Monday's session 1.59% lower at $1.86. A total volume of 1.65 million shares was traded. The Company's shares have advanced 23.18% in the last twelve months. The stock is trading above its 200-day moving average by 33.07%. Furthermore, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have a Relative Strength Index (RSI) of 40.74. Get the full research report on TRXC for free by clicking below at:
www.wallstequities.com/registration/?symbol=TRXC
Akers Biosciences
Shares in Thorofare, New Jersey headquartered Akers Biosciences Inc. ended at $0.26, up 7.98% from the last trading session. The stock recorded a trading volume of 11.87 million shares, which was above its three months average volume of 5.47 million shares. The Company's shares have gained 83.44% in the last month. The stock is trading below its 50-day moving average by 23.92%. Moreover, shares of Akers Biosciences, which together with its subsidiaries, focuses on the development and sale of disposable diagnostic testing devices to facilitate time sensitive therapeutic decisions in the US and internationally, have an RSI of 51.76. AKER's complimentary research coverage is a few simple steps away at:
www.wallstequities.com/registration/?symbol=AKER
Antares Pharma
Ewing, New Jersey headquartered Antares Pharma Inc.'s stock ended yesterday's session 3.10% higher at $2.33 with a total trading volume of 939,067 shares. The Company's shares have advanced 14.78% in the past month, 25.27% over the previous three months, and 20.10% in the last twelve months. The stock is trading above its 50-day moving average by 16.15%. Additionally, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 65.66. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ATRS at:
www.wallstequities.com/registration/?symbol=ATRS
Microbot Medical
On Monday, shares in Yokneam, Israel-based Microbot Medical Inc. recorded a trading volume of 364,061 shares. The stock finished the day flat at $1.05. The Company's shares have advanced 1.94% in the last month. The stock is trading below its 50-day moving average by 1.86%. Furthermore, shares of Microbot Medical, which engages in the research, design, development, and commercialization of micro-robotics medical technologies, have an RSI of 48.15.Aspiring Member, please take a moment to register below for your free research report on MBOT at:
www.wallstequities.com/registration/?symbol=MBOT
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-medical-supplies-stocks----transenterix-akers-biosciences-antares-pharma-and-microbot-medical-300590103.html
SOURCE Wall St. Equities
